Astellas and Pfizer's Xtandi plus ADT showed a decrease in mortality risk in a metastatic hormone-sensitive prostate cancer ...

Doctors examine a tumor in several different ways to determine whether a cancer is aggressive – and what kinds of treatments, if any, might work best.

The aggressiveness of a cancer is based on several factors, including the tumor's grade and stage, and the cells' genetic ...

New research reveals prostate cancer survivors face a significant long-term risk of developing a third primary cancer, with a ...

Black health experts discuss how clinical trials can help mitigate Black disease and reduce cancer to a chronic illness.

Researchers from City of Hope®, one of the largest and most advanced cancer research and treatment organizations in the United States with its National Medical Center named Top 5 "Best Hospital" in ...

Flatiron Health today announced 14 abstracts leveraging its high-quality real-world oncology data have been accepted for poster presentation and online publication at the 2025 American Society of ...

Forthcoming press releases will feature additional notable oral abstracts. More information on all MD Anderson ASCO Annual ...

Researchers from City of Hope®, one of the largest and most advanced cancer research and treatment organizations in the United States ...

Henry Butler is a prostate cancer survivor going on five years. He opens up about what recovery was like and how this journey ...

Donn Young is the former director of the Ohio State University Comprehensive Cancer Center Biostatistics Unit where he spent ...

The combination of enzalutamide with androgen deprivation therapy (ADT) significantly increases the chance of five-year survival for men with metastatic hormone-sensitive prostate cancer, according to ...